Current evidence indicates that angiogenesis plays an important role in the pathogenesis of several
malignancies, including breast cancer. Bevacizumab is a monoclonal antibody that targets the vascular endothelial growth
factor (VEGF). Recent clinical data have demonstrated that the addition of bevacizumab to first-line chemotherapy
improves the progression-free survival of patients with advanced breast cancer. This review presents an update on the role
of bevacizumab, as well as other anti-angiogenic agents in the management of patients with breast carcinoma.
Keywords: Angiogenesis, bevacizumab, breast cancer, treatment.
Rights & PermissionsPrintExport
Published on: 04 September, 2012
Page: [1230 - 1238]